NL-OMON42120尚未招募不适用
CCS in RA subjects compared to Type 2 DM - CCS in RA versus Type 2 DM
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion criteria for RA patients:
- •1) 40-< 60 years old.
- •2) Established RA according to the American College of Rheumatology 1987 Criteria [39];
- •3) Participation in the FRANCIS study which implies the availability of at least one recent cIMT measurement.
- •4) Written informed consent.;Inclusion criteria for type 2 DM patients
- •1) 40-< 60 years old;
- •2) Diagnosis of Type 2 Diabetes Mellitus according to national and international guidelines [40, 41];
- •3) Availability of at least one recent cIMT measurement;
- •4) Written informed consent.
排除标准
- •Exclusion criteria for RA:
- •1) RA patients with type 1 DM or Type 2 DM;
- •2) Severely decreased kidney function (MDRD under 30);
- •3) Cardiovascular event in history: cerebrovascular attack, acute myocardial infarction, CABG, PTCA and amputation, PTA or intermittent claudication due to peripheral artery disease. ;Exclusion criteria for DM type 2:
- •1) Presence of RA in Type 2 DM patients.
- •2) Severely decreased kidney function (MDRD under 30).
- •3) Cardiovascular event in history: cerebrovascular attack, acute myocardial infarction, CABG, PTCA and amputation, PTA or intermittent claudication due to peripheral artery disease.
研究者
相似试验
进行中（未招募）
1 期
Double ASCT in MM: phase III study comparing between melphalan based regimen vs a new regimen consisting of melphalan and thiotepaMedDRA version: 20.0Level: LLTClassification code 10028566Term: MyelomaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864multiple myelomaEUCTR2017-001013-89-ITAZIENDA OSPEDALIERA BIANCHI-MELACRINO-MORELLI292
招募中
2 期
AnRandomized Phase II Trial comparing CDDP plus S-1 with Bevacizumab and CDDP plus Pemetrexed with Bevacizumab against patients with Advanced Non-Squamous Non-Small Cell Lung CancerJPRN-UMIN000035401Gunma Hospital50
招募中
2 期
Randomized phase II trial of DCF-R vs CF-R in unresectable and recurrent esophageal cancerJPRN-UMIN000018443Gunma University Hospital Integrative center of general surgery52
进行中（未招募）
1 期
Randomized Phase 2 study comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining cetuximab with FOLFOX or FOLFIRI in RAS and B-RAF WT tumors.Potentialy or borderline resecable metastatic colorectal cancer(RAS and B-RAF W-T) at diagnosis and for whom a multidisciplinary meeting recommended chemotherapy first in a curative intent.EUCTR2012-005249-19-BECliniques universitaires Saint-Luc60
进行中（未招募）
1 期
Randomized Phase 2 study comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab with FOLFOX or FOLFIRI.Resecable Metastatic Cororectal Cancer.EUCTR2012-005376-34-BECliniques universitaires Saint-Luc60